

Press Release Archives**February 10, 2003****Withdrawal of Dealings**

Trading in the securities of the following 14 corporates under "Permitted to Trade" category shall be withdrawn with effect from April 01, 2003.

Sr.No.	Name of the company
1	Abbott India Limited
2	Atlas Copco (India) Limited
3	Aventis Pharma Limited (formerly known as Hoechst Marion Roussel Limited.)
4	Burroughs Wellcome (India) Limited
5	Carrier Aircon (India) Limited
6	Gillette (India) Limited
7	Henkel Spic India Limited
8	Hindustan Zinc Limited
9	Krone Communications Limited
10	Philips India Limited
11	Procter & Gamble India Limited
12	Punjab Communications Limited
13	Rayban Sun Optics Limited
14	Tata Infotech Limited

The Exchange shall consider listing the above companies as and when they indicate their interest to list and upon them fulfilling the eligibility criteria for listing.

[Top](#)

Press reports regarding M/s. Aptech Training Ltd.

The press had reports on February 07, 2003 that the Debt Recovery Tribunal (DRT) II at Chennai passed an interim direction restraining Aptech Training Limited's promoter, Atul K. Nishar from transferring or selling his shares in the company.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Aptech Training Limited has vide its letter inter-alia stated, "You will note that as per records Mr. Atul Nishar is not a shareholder in the Company. Hence, the proceedings pending in Debt Recovery Tribunal and any orders passed thereunder would not be relevant with regard to the Company. The Promoters have not entered into any Agreement for sale of shares. In any case, as noted above, Mr. Nishar is not holding any shares in the Company and therefore, the news item is misconceived."

[Top](#)

Press reports regarding M/s. Alstom Power India Ltd.

The press had reports that Alstom Power India Limited has bagged a Rs. 250-crore contract from Jaiprakash Power Ventures Limited for supply of hydro-electric power plant equipment for the latter's 400 MW Vishnuprayag project located in Uttaranchal.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Alstom Power India Limited has vide its letter inter-alia stated, "Alstom has signed a 50 million Euro (about Rs. 250 crore) contract with Jaiprakash Power Ventures Ltd. (JVPL), India for the supply of major Hydro-Generating Plant Equipment for the 400 MW (4 x 100 MW) Vishnuprayag Hydroelectric Project located on the Alaknanda river in Uttaranchal. The turnkey contract covers the supply and supervision of erection of turbines, governing systems, spherical valves, butterfly valves, generators, static excitation system, bus ducts, computerized power plant control and monitoring systems and 400 kv GIS and cables. The project will be managed by Alstom's Hydro Power Segment in France, equipment and components being supplied from the Company's manufacturing facilities in Grenoble and Belfort, France, and also from India. The Project is scheduled for commissioning in December 2006. The project, designed to produce over two billion units of power, is expected to mitigate the power shortage in North India when commissioned."

[Top](#)

Press reports regarding M/s. State Bank of India

The press had reports on February 07, 2003 that the government will allow a higher foreign holding in State Bank of India.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

State Bank of India has vide its letter inter-alia stated, "We advise that we have no official communication from Reserve Bank of India with regard to higher foreign holding in the Bank.

[Top](#)

Press reports regarding M/s. Glenmark Pharmaceuticals Ltd.

The press had reports that Glenmark Pharmaceuticals Limited is divesting its stake from its 100% subsidiary Glenmark Laboratories, for a consideration of Rs. 35 crore.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Reply is awaited from Glenmark Pharmaceuticals Limited.

[Top](#)